JW (Cayman) Therapeutics Co Ltd
HKEX:2126
JW (Cayman) Therapeutics Co Ltd
HKEX:2126
Price:
2.17 HKD
0.46%
Updated:
May 31, 2024
JW (Cayman) Therapeutics Co Ltd
Capital Expenditures
|
JW (Cayman) Therapeutics Co Ltd
Capital Expenditures Peer Comparison
Comparables:
6160
1801
603392
300122
300896
Competitive Capital Expenditures Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
JW (Cayman) Therapeutics Co Ltd
HKEX:2126
|
Capital Expenditures
-¥14.6m
|
CAGR 3-Years
52%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Capital Expenditures
-¥4.1B
|
CAGR 3-Years
-61%
|
CAGR 5-Years
-42%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Capital Expenditures
-¥1.4B
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Capital Expenditures
-¥1.2B
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
N/A
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Capital Expenditures
-¥1.1B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-18%
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Capital Expenditures
-¥155.7m
|
CAGR 3-Years
-68%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
See Also
What is JW (Cayman) Therapeutics Co Ltd's Capital Expenditures?
Capital Expenditures
-14.6m
CNY
-14.6m
CNY
Based on the financial report for Dec 31, 2023, JW (Cayman) Therapeutics Co Ltd's Capital Expenditures amounts to -14.6m CNY.
What is JW (Cayman) Therapeutics Co Ltd's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
20%
20%
Over the last year, the Capital Expenditures growth was 86%. The average annual Capital Expenditures growth rates for JW (Cayman) Therapeutics Co Ltd have been 52% over the past three years , 20% over the past five years .
You don't have any saved screeners yet
